Showing 8801-8810 of 10270 results for "".
- Merz and Christie Brinkley Partner to Launch “Milestones of Me” Campaignhttps://practicaldermatology.com/news/merz-and-christie-brinkley-partner-to-launch-milestones-of-me-campaign/2459922/Merz Americas is partnering with supermodel, actress, and entrepreneur, Christie Brinkley, to launch its “Milestones of Me” campaign, which encourages women to celebrate the moments, big or small, that have made them who they are today. The campaign, which kicks off in honor of Christ
- Keloids May Up Breast Cancer Riskhttps://practicaldermatology.com/news/keloids-may-up-breast-cancer-risk/2459925/Keloids may be associated with an increased risk breast cancer, particularly among African Americans, a new study suggests. The research team hypothesized African American women with a history of keloids would reflect a population of breast cancer patients with aggressive tumors and poor
- Dermatologists Call for Changes to Off-label Coverage Decisionshttps://practicaldermatology.com/news/dermatologists-call-for-changes-to-off-label-coverage-decisions/2459926/Dermatologists report major inconsistencies in Medicare Reimbursement Policy for off-label prescriptions and are now calling for an appeal process for cases where coverage is denied. Researchers from several institutions, including the Perelman School of Medicine at the University of Pennsylvania
- L'Occitane to Buy ELEMIS for $900 Millionhttps://practicaldermatology.com/news/loccitane-to-buy-elemis-for-900-million/2459939/L’Occitane International S.A. has entered into a definitive agreement to acquire ELEMIS, the number one luxury British skincare brand, for $900 million in cash. ELEMIS is being sold by Steiner Leisure Limited. Reinold Geiger, Chairman and Chief Executive Officer of L’OCCITANE
- “Christmas Berry” Plant Compound Could Fight Uveal Melanomahttps://practicaldermatology.com/news/christmas-berry-plant-compound-could-fight-uveal-melanoma/2459945/A compound extracted from the Christmas berry primrose plant may stops the growth of uveal melanoma, according to preliminary tests. With further testing, the discovery could lead to new therapeutic options for patients with uveal melanoma, report researches from the
- Modernizing Medicine Introduces New Patient Engagement Toolshttps://practicaldermatology.com/news/modernizing-medicine-introduces-new-patient-engagement-tools/2459951/Modernizing Medicine has launched enhanced patient engagement tools powered by Relatient that are designed to reduce no-shows and improve patient compliance, satisfaction, and operational efficiency. Patients who do not show for appointments can be a significant cost and ef
- EWG VERIFIED Goes Mainstream with Herbal Essences Shampooshttps://practicaldermatology.com/news/ewg-verified-goes-mainstream-with-herbal-essences-shampoos/2457544/
- New Xeomin "Later Haters" Campaign Urges Women to “X” Out Judgmenthttps://practicaldermatology.com/news/new-xeomin-later-haters-campaign-aims-to-x-out-judgment/2457487/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to f
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm
- Candela, VBF Provide Laser Treatments to Families Including a Special Toddlerhttps://practicaldermatology.com/news/candela-vbf-provide-laser-treatments-to-families-including-a-special-toddler/2457498/